Your browser doesn't support javascript.
loading
Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease.
Shiffman, Mitchell; Freilich, Bradley; Vuppalanchi, Raj; Watt, Kymberly; Chan, Jean L; Spada, Al; Hagerty, David T; Schiff, Eugene.
Afiliação
  • Shiffman M; Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, Virginia.
  • Freilich B; Kansas City Research Institute, Kansas City, Missouri.
  • Vuppalanchi R; Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana.
  • Watt K; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
  • Chan JL; Conatus Pharmaceuticals Inc., San Diego, California.
  • Spada A; Conatus Pharmaceuticals Inc., San Diego, California.
  • Hagerty DT; Conatus Pharmaceuticals Inc., San Diego, California.
  • Schiff E; Schiff Center for Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida.
Aliment Pharmacol Ther ; 49(1): 64-73, 2019 01.
Article em En | MEDLINE | ID: mdl-30430605
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácidos Pentanoicos / Alanina Transaminase / Caspase 3 / Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácidos Pentanoicos / Alanina Transaminase / Caspase 3 / Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article